Malaria Vaccine Candidate RTS,S/AS01 Phase 3 Clinical Trial Results
Thursday, April 23, 2015 - 16:50
in Health & Medicine
The first malaria vaccine candidate (RTS,S/AS01) to reach phase 3 clinical testing is partially effective against clinical disease in young African children up to 4 years after vaccination, according to final trial data published in The Lancet. read more